IRCCS Istituto Oncologico Veneto (IOV), Padua, Italy.
Unit of Hematology and Transplant, Dipartimento di Area Medica (DAME), University Hospital of Udine, Udine, Italy.
Minerva Med. 2020 Oct;111(5):395-410. doi: 10.23736/S0026-4806.20.07019-6. Epub 2020 Sep 21.
After being in the therapeutic wilderness for several decades, acute myeloid leukemia has been recently thrust into the limelight with a series of drug approvals. Technical refinements in production, genetic manipulation and chemical modification of monoclonal antibodies led to growing interest in antibodies-based treatment strategies. Much of the focus of these efforts in acute myeloid leukemia has been on CD33 as a target. On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refractory CD33 acute myeloid leukemia. This signals a new chapter in the long and unusual story of gemtuzumab ozogamicin, which was the first antibody-drug conjugate approved for human use by the Food and Drug Administration. In this review we have analyzed the history of this drug which, among several mishaps, is experiencing a second youth and still represents a field to be further explored.
在经历了几十年的治疗困境后，急性髓细胞白血病最近因一系列药物批准而备受关注。单克隆抗体生产、遗传操作和化学修饰方面的技术改进，使得人们对基于抗体的治疗策略产生了越来越大的兴趣。在急性髓细胞白血病中，这些努力的重点大多集中在 CD33 作为靶点上。2017 年 9 月 2 日，美国食品和药物管理局批准吉妥珠单抗奥佐米星用于治疗复发或难治性 CD33 急性髓细胞白血病。这标志着吉妥珠单抗奥佐米星这一漫长而不寻常故事的新篇章，它是食品和药物管理局批准的第一个用于人类的抗体药物偶联物。在这篇综述中，我们分析了这种药物的历史，它经历了几次挫折，正在迎来第二个青春，仍然代表着一个有待进一步探索的领域。
